Sign In
2 Apr 2012 15:25
ο»Ώ
ARK THERAPEUTICS GROUP PLC
Β
31 March 2012
Β
Annual Information Update
Β
Β
Ark Therapeutics Group plc (the "Company") is pleased to provide an annual information update in accordance with the requirements of Prospectus Rule 5.2. This update refers to information that has been published or made available by or for the Company to the public in the 12 months up to and including 31 March 2012.
Β
The following UK regulatory announcements have been made via the Regulatory News Service provided by the London Stock Exchange:
Β
Date | Headline |
31 March 2011 | Annual Information Update |
9 May 2011 | AGM Results |
17 May 2011 | Interim Management Statement |
3 June 2011 | Block Listing Interim Review |
13 June 2011 | Price Monitoring Extension |
13 June 2011 | Second Price Monitoring Extension |
4 July 2011 | Grant of US Patents and Milestone Payments |
6 July 2011 | Ark receives Finnish Grants |
14 July 2011 | Wins β¬5.3 million EU Framework Programme 7 Grant |
18 July 2011 | Holding(s) in Company |
25 July 2011 | Price Monitoring Extension |
25 July 2011 | Second Price Monitoring Extension |
29 July 2011 | Price Monitoring Extension |
29 July 2011 | Second Price Monitoring Extension |
1 August 2011 | Holding(s) in Company |
24 August 2011 | Half Yearly Report - Part 1 |
24 August 2011 | Half Yearly Report - Part 2 |
24 August 2011 | Half Yearly Report on National Storage Mechanism |
12 September 2011 | Re: Agreement |
16 September 2011 | Price Monitoring Extension |
16 September 2011 | Second Price Monitoring Extension |
3 November 2011 | Manufacturing Agreement |
9 November 2011 | Interim Management Statement |
5 December 2011 | Block Listing Interim Review |
7 December 2011 | Director/PDMR Shareholding |
4 January 2012 | Manufacturing update |
16 January 2012 | Change of Broker |
8 February 2012 | US Patent for Neuropilin-1 Receptor |
9 February 2012 | Notice of Results |
23 February 2012 | Holding(s) in Company |
12 March 2012 | Final Results |
13 March 2012 | Board Changes |
15 March 2012 | Director/PDMR Shareholding |
26 March 2012 | Change of Broker Name |
Β
Copies of all regulatory announcements for Ark Therapeutics Group plc can be found on the Press Release Archive page on the Company's website www.arktherapeutics.com
Β
Documents sent to shareholders and filed with the UKLA Document Viewing Facility (now the National Storage Mechanism):
Β
Date of Filing | Document |
10 May 2011 | 2011 AGM Resolutions |
24 August 2011 | 2011 Interim Report |
21 March 2012 | Annual Report and Accounts for the year ended 31 December 2011 (including Notice of 2012 Annual General Meeting) |
21 March 2012 | 2012 Annual General Meeting Proxy form |
Β
Documents filed with the UKLA's National Storage Mechanism can be obtained from: www.hemscott.com/nsm.do.
Β
The 2011 AGM Resolutions and 2011 Annual Report and Accounts are also available either on the Company's website www.arktherapeutics.com or, as well as the other documents listed above, on application to the Company Secretary.
Β
The Company has also made the following filings at Companies House:
Β
Date of Filing | Document filed |
10 May 2011 | 2011 AGM Resolutions |
10 May 2011 | Form AD01 - Change of Registered Office |
10 May 2011 | Form CH01 - Change of Directors Details |
10 May 2011 | Form CH01 - Change of Directors Details |
10 May 2011 | Form CH01 - Change of Directors Details |
10 May 2011 | Form CH01 - Change of Directors Details |
10 May 2011 | Form CH01 - Change of Directors Details |
2 November 2011 | Form CH01 - Change of Directors Details |
2 November 2011 | Form AR01 - Annual Return |
14 March 2012 | AP01 - Appointment of Director |
Β
Copies of these documents may be obtained from Companies House, Crown WayMaindy, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk.
Β
Further information is available regarding the Company and its activities on its website www.arktherapeutics.com.
Β
The information referred to in this update was up to date at the time the information was published, but some information may now be out of date.
Β
Enquiries:
Β
Ark Therapeutics Group plc Dr Edward Bliss, Company Secretary | 020 7388 7722 |
Β
Follow the stocks
